Sir,

Hepatitis C virus (HCV) is a major life threat among hemodialysis (HD) patients with prevalence of 4.3%-45.2% in India.\[[@ref1]\] Major challenge is that anti-HCV which is usually a reliable marker for HCV is often negative in HD patients despite the presence of significant viremia, making molecular tests the most reliable tests for screening HCV infection in HD patients.\[[@ref2]\] Goal of this study was to find out the utility of HCV RNA as a screening marker for HCV infection in HD patients.

In this one year retrospective study, blood samples of 410 chronic kidney disease (CKD) patients were included. Anti-HCV was tested by chemiluminescence microparticle immunoassay (Architect i1000SR, Abbott Diagnostics, USA), and HCV RNA was tested by real-time PCR (Abbott m2000rt). Institutional Ethics Committee of our institute approved the study protocol.

Among 410 CKD patients, 128 (31%) were on HD and overall HCV infection among 128 HD patients was seen in 17 (13.3%) patients with 12 (9.4%) patients positive for anti-HCV and 12 (9.4%) patients positive for HCV RNA. A total of 7 (5.5%) patients were positive for both anti-HCV and HCV RNA suggesting active infection. A total of 5 (4%) patients were HCV RNA negative but anti-HCV positive with low signal/cut-off ratio who persistently remained HCV RNA negative till 1 year follow-up, thus suggesting false anti-HCV positivity.\[[@ref3]\] Totally 5 (4%) asymptomatic HD patients with undetectable antibodies were HCV RNA positive proving that anti-HCV alone is not a good screening marker for HCV detection among HD patients [table 1](#T1){ref-type="table"}. Our study results correlate well with two other studies.\[[@ref4][@ref5]\]
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Seronegative HCV infection among HD patients can be due to longer window period in these immunocompromised individuals\[[@ref4]\] or due to the presence of antigen-antibody immune complexes, resulting in low anti-HCV response.\[[@ref2]\] Hence, we recommend that all HD patients should be screened by both anti-HCV and HCV RNA to rule out HCV infection with high sensitivity.
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